-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Denali Therapeutics, Maintains $32 Price Target

Benzinga·12/05/2025 10:37:34
语音播报
BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $32 price target.